Known targets — ChEMBL curated mechanism
BCL2BCL2A1BCL2L1BCL2L10BCL2L2MCL1
The experimentally established mechanism targets of Obatoclax. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 known ✓ | Q07817 | 2/20 | 0.47 |
| ▸ | BCL2 known ✓ | P10415 | 1/20 | 0.37 |
| ▸ | MCL1 known ✓ | Q07820 | 1/20 | 0.37 |
| ▸ | BCL2A1 known ✓ | Q16548 | 1/20 | 0.37 |
| ▸ | BCL2L2 known ✓ | Q92843 | 1/20 | 0.37 |
| ▸ | BCL2L10 known ✓ | Q9HD36 | 1/20 | 0.37 |
| ▸ | ASPH | Q12797 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | BAD | Q92934 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Obatoclax SCHEMBL29358370 | 1.00 | BCL2L1 (0.47) | BCL2L1ASPHKDM4EMAPTRAB9A | |
| Obatoclax SCHEMBL681264 | 1.00 | BCL2L1 (0.47) | BCL2L1ASPHKDM4EMAPTRAB9A | |
| Obatoclax SCHEMBL15201882 | 1.00 | BCL2L1 (0.47) | BCL2L1ASPHKDM4EMAPTRAB9A | |
| Obatoclax SCHEMBL631677 | 0.93 | RAB9A (0.41) | BCL2L1ASPHKDM4EMAPTRAB9A | |
| Obatoclax SCHEMBL29354696 | 0.93 | RAB9A (0.41) | BCL2L1ASPHKDM4EMAPTRAB9A | |
| Obatoclax SCHEMBL2751250 | 0.93 | RAB9A (0.41) | BCL2L1ASPHKDM4EMAPTRAB9A | |
| Obatoclax SCHEMBL29519876 | 0.93 | RAB9A (0.41) | BCL2L1ASPHKDM4EMAPTRAB9A | |
| Obatoclax SCHEMBL631676 | 0.93 | RAB9A (0.41) | BCL2L1ASPHKDM4EMAPTRAB9A | |
| SCHEMBL630995 | 0.83 | AURKA (0.37) | BCL2L1ASPHKDM4EMAPTRAB9A | |
| SCHEMBL630994 | 0.83 | AURKA (0.37) | BCL2L1ASPHKDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230579-B2 | Method of treating BCL-2 over-expressing disorders using arts containing a BH3-like domain | CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2022-01-25 | — | — | US | claimed |
| EP-2814839-B1 | ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS | CARMEL HAIFA UNIV ECONOMIC CORPORATION LTD (IL) | 2019-08-28 | — | — | EP | claimed |
| US-20170081380-A1 | ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS | CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2017-03-23 | — | — | US | claimed |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-02-18 | — | — | US | claimed |
| EP-2976354-A1 | STAPLING eIF4E INTERACTING PEPTIDES | Agency For Science, Technology And Research (SG) | 2016-01-27 | — | — | EP | claimed |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-03 | — | — | US | claimed |
| EP-2904000-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | Agency for Science, Technology and Research (SG) | 2015-08-12 | — | — | EP | claimed |
| EP-2814839-A1 | ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS | Carmel-Haifa University Economic Corporation Ltd. (IL) | 2014-12-24 | — | — | EP | claimed |
| WO-2014149001-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-09-25 | — | — | WO | claimed |
| WO-2014055039-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-04-10 | — | — | WO | claimed |
| WO-2013121428-A1 | ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS | CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2013-08-22 | — | — | WO | claimed |
| US-20250025469-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-11944631-B2 | Combination therapies | INFINITY PHARMACEUTICALS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-11866409-B2 | Apoptosis related protein in the tgf-beta signaling pathway (ARTS) mimetic compounds, compositions, methods and uses thereof in induction of differentiation and/or apoptosis of premalignant and malignant cells, thereby restoring their normal-like phenotype | CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2024-01-09 | — | — | US | disclosed |
| EP-3331546-B1 | CXCR4 INHIBITOR FOR THE TREATMENT OF CANCER | BIOKINE THERAPEUTICS LTD (IL) | 2023-10-04 | — | — | EP | disclosed |
| WO-2013121428-A1 | ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS | CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2013-08-22 | — | — | WO | disclosed |
| EP-2604277-A1 | Combination therapy of a type II anti-CD20 antibody with an anti-Bcl-2 active agent | Roche Glycart AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-20120276085-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | Hoffman-La Roche. Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20110287006-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | Hoffman-La Roche. Inc. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110086025-A1 | Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active Agent | Hoffman-La Roche. Inc. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025469-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL3 | BCL2L1 6/4885BCL2 1/4885MCL1 4/4885 |
| US-11944631-B2 | Combination therapies | BCL2, BAK1, BCL3 | BCL2L1 6/4885BCL2 1/4885MCL1 4/4885 |
| US-20110287006-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | BCL2L1 7/4885BCL2 2/4885MCL1 13/4885 |
| US-20120276085-A1 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT | BAK1, BCL2, BCL3 | BCL2L1 7/4885BCL2 2/4885MCL1 13/4885 |
| US-20110086025-A1 | Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active Agent | BAK1, BCL2, BCL3 | BCL2L1 7/4885BCL2 2/4885MCL1 13/4885 |
| US-11866409-B2 | Apoptosis related protein in the tgf-beta signaling pathway (ARTS) mimetic compounds, compositions, methods and uses thereof in induction of differentiation and/or apoptosis of premalignant and malignant cells, thereby restoring their normal-like phenotype | BID, XIAP, BAD | BCL2L1 8/4885BCL2 12/4885MCL1 9/4885 |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | EIF4EBP1, EIF4E, EIF4G2 | BCL2L1 1047/4885BCL2 2339/4885MCL1 1895/4885 |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | TP53, MDM4, MDM2 | BCL2L1 129/4885BCL2 136/4885MCL1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.